Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 1 de 1
Filtre
1.
Clinical Psychopharmacology and Neuroscience ; : 446-449, 2019.
Article | WPRIM | ID: wpr-763546

Résumé

Methylphenidate (MPH) is the most preferred drug for treatment of the attention deficit hyperactivity disorder (ADHD). Here, we aimed to discuss the possible effects and mechanisms of MPH on precocious puberty (PP) via a case series with seven children who had normal body mass index. In this case series we evaluated seven children with ADHD, who had received MPH for at least 6 months (0.5 mg/kg/dose three times a day, maximum 60 mg) and admitted to Department of Pediatric Endocrinology with PP symptoms. The mean age was 8.16 years. Basal hormonal levels (luteinizing hormone [LH], follicle stimulating hormone, and estrogen/testosterone) were within normal range. Results of LH-releasing hormone stimulation tests demonstrated central pubertal responses. Glutamine, dopamine and noradrenaline are most important excitatory neurotransmitters that have a role at the beginning of puberty. The effect of MPH, cumulating dopamine and noradrenaline in the synaptic gap could be associated with the acceleration of puberty with the excitatory effect of dopamine’s gonadotropin-releasing hormone (GnRH) release, excitatory effect of noradrenaline’s GnRH release and the disappearance of GnRH receptor expression suppressor effect on prolactin disinhibitory effect.


Sujets)
Adolescent , Enfant , Humains , Accélération , Trouble déficitaire de l'attention avec hyperactivité , Indice de masse corporelle , Dopamine , Endocrinologie , Hormone folliculostimulante , Glutamine , Hormone de libération des gonadotrophines , Méthylphénidate , Agents neuromédiateurs , Norépinéphrine , Prolactine , Puberté , Puberté précoce , Récepteurs à la gonadolibérine , Valeurs de référence
SÉLECTION CITATIONS
Détails de la recherche